EPAS1 and metabolic disease: HIF-2α antagonists such as PT-2385 ((S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzoniltrile) are increasingly being proposed as a potential effective treatment of choice for HIF-2α-related tumors and metabolic disorders [10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26].